Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011

Inclusion Criteria: * Healthy male or female * Body mass index (BMI) within 18.0 kg/m2 to 30.0 kg/m\^2, inclusively * Female participants must not be pregnant, breastfeeding or intend to become pregnant through 1 year post-administration * Male subjects must agree to not cause pregnancy or donate sperm for 1 year post-administration * Non-smoker * Agree to abstain from alcohol for 72 hours and caffeine for 48 hours prior to administration and during the confinement period * Agree to not donate blood or plasma during study participation * Agree not to travel to Rift Valley fever virus (RVFV) endemic areas during participation Exclusion Criteria: * Known history of RVFV infection * Previous receipt of RVFV vaccine * Illness with fever within 5 days prior to administration * History of malignancy within prior 5 years * History of significant cardiovascular, pulmonary, gastrointestinal, liver, kidney, hematologic, neurological, psychiatric, endocrine, immunologic, dermatologic disease * History of hypersensitivity reaction * History or clinical evidence of alcohol abuse * Human immunodeficiency virus (HIV) positive * Hepatitis C virus positive * Hepatitis B virus positive * Received immunoglobulin or antibody product within 6 months of administration * Vaccine within 28 days of administration * Received investigational agent within 3 months or \< 5 half-lives (whichever is longer) prior to administration * Donation of plasma, 1 unit or \> 500 mL blood donation in 56 days prior…